PIZZUTI, Laura
 Distribuzione geografica
Continente #
NA - Nord America 1.349
EU - Europa 526
AS - Asia 131
AF - Africa 10
SA - Sud America 2
Totale 2.018
Nazione #
US - Stati Uniti d'America 1.333
IT - Italia 188
SE - Svezia 167
IN - India 68
DE - Germania 41
FI - Finlandia 38
CN - Cina 26
GB - Regno Unito 20
SG - Singapore 20
UA - Ucraina 17
CA - Canada 16
RO - Romania 12
BG - Bulgaria 11
IE - Irlanda 10
IR - Iran 8
TG - Togo 7
FR - Francia 6
CH - Svizzera 4
HK - Hong Kong 4
NL - Olanda 4
AR - Argentina 2
ES - Italia 2
KZ - Kazakistan 2
SC - Seychelles 2
BE - Belgio 1
DK - Danimarca 1
EE - Estonia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 2.018
Città #
Fairfield 210
Ashburn 103
Woodbridge 101
Seattle 99
Houston 95
Chandler 90
Wilmington 84
Cambridge 82
Rome 68
Princeton 41
San Paolo di Civitate 41
Helsinki 32
Dearborn 29
New York 29
Ann Arbor 25
Lawrence 25
Millbury 23
Bremen 19
Andover 16
Sacramento 16
Ottawa 14
San Diego 14
Beijing 12
Plano 11
Sofia 11
Boston 9
Dublin 8
Norwalk 8
Lomé 7
Surrey 7
Leawood 6
Singapore 6
Jacksonville 5
Bühl 4
Hong Kong 4
Phoenix 4
Zanjan 4
Falls Church 3
Glasgow 3
Milan 3
Torino 3
Bengaluru 2
Birmingham 2
Boardman 2
Bovisio-Masciago 2
Buffalo 2
Edinburgh 2
Federal 2
Formello 2
Fort Worth 2
Frankfurt am Main 2
Fremont 2
Groningen 2
Guangzhou 2
Kish 2
Levallois-perret 2
Livorno 2
London 2
Madrid 2
Magenta 2
Naples 2
Redwood City 2
Shenyang 2
Toronto 2
Trumbull 2
Zhengzhou 2
Almaty 1
Amsterdam 1
Augusta 1
Balasore 1
Bangkok 1
Berlin 1
Bern 1
Bratislava 1
Carlentini 1
Castellana Grotte 1
Catania 1
Chieti 1
Ercolano 1
Falkenstein 1
Frattamaggiore 1
Fuzhou 1
Guidonia 1
Guidonia Montecelio 1
Hefei 1
Henderson 1
Izmir 1
Kashan 1
Kraainem 1
Liverpool 1
Menlo Park 1
Minturno 1
Muizenberg 1
Nanjing 1
Oral 1
Pavia 1
Quzhou 1
Santa Clara 1
Shanghai 1
Southend 1
Totale 1.458
Nome #
The sexist behaviour of immune checkpoint inhibitors in cancer therapy? 116
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 103
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab 99
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study 96
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 94
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer 87
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 85
Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients 81
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer. Potential molecular mechanisms, clinical implications and future perspectives 77
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting 67
Neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. The DECT trial 66
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients. A multicenter Italian experience 64
The impact of locoregional treatment on response to Nivolumab in advanced platinum refractory head and neck cancer: the NEED TRIAL 64
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome 62
Non-pegylated liposomal doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients 60
Autoantibodies specific to ERa are involved in tamoxifen resistance in hormone receptor positive breast cancer 59
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 57
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 56
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy 55
null 54
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 54
Immnunohistochemical Expression and Prognostic Significance of Fatty Acid Synthase in Pancreatic Carcinoma 52
Immunotherapy in HER2-positive breast cancer. state of the art and future perspectives 52
null 52
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials 50
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 46
Role of chemotherapy in vulvar cancers: time to rethink standard of care? 43
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience 36
Observational multicenter study on the prognostic relevance of coagulation activation in risk assessment and stratification in locally advanced breast cancer. Outline of the arias trial 32
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 32
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature 29
Circulating hpv dna in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives 28
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial 27
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer 22
null 21
Burnout of health care providers during the covid-19 pandemic: Focus on medical oncologists 19
Biomarkers of response and resistance to CDK4/6 inhibitors in breast cancer: hints from liquid biopsy and microRNA exploration 18
Neoadjuvant endocrine therapy in breast cancer. Current knowledge and future perspectives 17
null 16
Prognostic relevance of neutrophil to lymphocyte ratio (Nlr) in luminal breast cancer: A retrospective analysis in the neoadjuvant setting 16
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 15
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 12
Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer 12
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 11
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B 10
Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors 7
Sexual dysfunctions in breast cancer patients. Evidence in context 5
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study 3
Totale 2.239
Categoria #
all - tutte 6.438
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.438


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201991 0 0 0 0 0 0 0 0 0 16 38 37
2019/2020512 26 14 40 25 56 67 62 63 54 53 26 26
2020/2021259 33 13 14 16 4 8 2 10 28 103 25 3
2021/2022470 8 7 25 25 81 34 10 33 27 26 133 61
2022/2023599 121 114 46 43 68 47 18 46 44 10 33 9
2023/2024238 9 35 10 28 30 47 11 41 9 18 0 0
Totale 2.239